177 Lu-Dota-NOCate & 177 Lu-Dota-Gastrin in Metastatic Medullary Thyroid Cancer Clinic of...
-
Upload
audrey-carroll -
Category
Documents
-
view
217 -
download
2
Transcript of 177 Lu-Dota-NOCate & 177 Lu-Dota-Gastrin in Metastatic Medullary Thyroid Cancer Clinic of...
![Page 1: 177 Lu-Dota-NOCate & 177 Lu-Dota-Gastrin in Metastatic Medullary Thyroid Cancer Clinic of Endocrinology, Inst. of Nuclear Medicine, University Hospital,](https://reader035.fdocuments.net/reader035/viewer/2022062722/56649f2c5503460f94c47171/html5/thumbnails/1.jpg)
177177Lu-Dota-NOCateLu-Dota-NOCate &&
177177Lu-Dota-GastrinLu-Dota-Gastrin in in
Metastatic Medullary Thyroid CancerMetastatic Medullary Thyroid Cancer
Clinic of Endocrinology, Inst. of Nuclear Medicine, University Hospital, Basel, CH
For Questions contact:
Beat Müller, [email protected]
Martin A. Walter, [email protected]
![Page 2: 177 Lu-Dota-NOCate & 177 Lu-Dota-Gastrin in Metastatic Medullary Thyroid Cancer Clinic of Endocrinology, Inst. of Nuclear Medicine, University Hospital,](https://reader035.fdocuments.net/reader035/viewer/2022062722/56649f2c5503460f94c47171/html5/thumbnails/2.jpg)
Medullary Thyroid Cancer
Treatment Options:
- Surgery (first line)
- To date no effective systemic treatment option
- Radiation Therapy is not well defined
- Treatment options with different Radiopeptides are currently evaluated
![Page 3: 177 Lu-Dota-NOCate & 177 Lu-Dota-Gastrin in Metastatic Medullary Thyroid Cancer Clinic of Endocrinology, Inst. of Nuclear Medicine, University Hospital,](https://reader035.fdocuments.net/reader035/viewer/2022062722/56649f2c5503460f94c47171/html5/thumbnails/3.jpg)
Aim
To assess the value of177Lu-Dota-NOCate and 177Lu-Dota-Gastrin
in Imaging and Treatment of
Metastatic Medullary Thyroid Cancer
Ethically Approved (EKBB)
![Page 4: 177 Lu-Dota-NOCate & 177 Lu-Dota-Gastrin in Metastatic Medullary Thyroid Cancer Clinic of Endocrinology, Inst. of Nuclear Medicine, University Hospital,](https://reader035.fdocuments.net/reader035/viewer/2022062722/56649f2c5503460f94c47171/html5/thumbnails/4.jpg)
Radiopeptides
Target
Somatostatin/
CCK2-Receptor
Ligand
Somatostatin/
Gastrin-Analogs
Signal
177Lu
![Page 5: 177 Lu-Dota-NOCate & 177 Lu-Dota-Gastrin in Metastatic Medullary Thyroid Cancer Clinic of Endocrinology, Inst. of Nuclear Medicine, University Hospital,](https://reader035.fdocuments.net/reader035/viewer/2022062722/56649f2c5503460f94c47171/html5/thumbnails/5.jpg)
„Magic Bullet“ Approach
Application Distribution Accumulation
Tumor
Metastases
![Page 6: 177 Lu-Dota-NOCate & 177 Lu-Dota-Gastrin in Metastatic Medullary Thyroid Cancer Clinic of Endocrinology, Inst. of Nuclear Medicine, University Hospital,](https://reader035.fdocuments.net/reader035/viewer/2022062722/56649f2c5503460f94c47171/html5/thumbnails/6.jpg)
Affinity Profile (Dota-NOC-ATE)
![Page 7: 177 Lu-Dota-NOCate & 177 Lu-Dota-Gastrin in Metastatic Medullary Thyroid Cancer Clinic of Endocrinology, Inst. of Nuclear Medicine, University Hospital,](https://reader035.fdocuments.net/reader035/viewer/2022062722/56649f2c5503460f94c47171/html5/thumbnails/7.jpg)
Receptor Profile (MTC)
EB Forssell-Aronsson. J Nucl Med 2000;41:636–642
![Page 8: 177 Lu-Dota-NOCate & 177 Lu-Dota-Gastrin in Metastatic Medullary Thyroid Cancer Clinic of Endocrinology, Inst. of Nuclear Medicine, University Hospital,](https://reader035.fdocuments.net/reader035/viewer/2022062722/56649f2c5503460f94c47171/html5/thumbnails/8.jpg)
Pilot-Patient (Dota-NOC-ATE)
SpecificTumor Uptake(LN-metastesis)
p9581♂, 63yMetastised MTC
![Page 9: 177 Lu-Dota-NOCate & 177 Lu-Dota-Gastrin in Metastatic Medullary Thyroid Cancer Clinic of Endocrinology, Inst. of Nuclear Medicine, University Hospital,](https://reader035.fdocuments.net/reader035/viewer/2022062722/56649f2c5503460f94c47171/html5/thumbnails/9.jpg)
Patients
Patients with progressive MTC
Exclusion criteria:
• Karnofsky Performance Status < 50%
• Refusion of a 1-year contraception
• Pregnancy
• Breast-feeding
• Age<18
![Page 10: 177 Lu-Dota-NOCate & 177 Lu-Dota-Gastrin in Metastatic Medullary Thyroid Cancer Clinic of Endocrinology, Inst. of Nuclear Medicine, University Hospital,](https://reader035.fdocuments.net/reader035/viewer/2022062722/56649f2c5503460f94c47171/html5/thumbnails/10.jpg)
Diagnostic Scintigraphy
• Scintigraphy + Dosimetry
(first compound, outpatient, 2d)
• Scintigraphy + Dosimetry
(second compound, outpatient, 2d)
2 weeks later
• Significant Accumulation
+ Favorable Biodistribution → Treatment
![Page 11: 177 Lu-Dota-NOCate & 177 Lu-Dota-Gastrin in Metastatic Medullary Thyroid Cancer Clinic of Endocrinology, Inst. of Nuclear Medicine, University Hospital,](https://reader035.fdocuments.net/reader035/viewer/2022062722/56649f2c5503460f94c47171/html5/thumbnails/11.jpg)
Treatment
• Inpatient
• 3 Days
• Day 1: Injection of Radiopeptide
+ Amino Acid Infusion (Kidney Protection)
• Day 2: Imaging
• Day 3: Release of Patient